We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genentech Recaps Bid to Keep Avastin’s MBC Indication
Genentech Recaps Bid to Keep Avastin’s MBC Indication
May 20, 2011
Genentech has highlighted three key reasons why the FDA should maintain Avastin’s metastatic breast cancer (MBC) indication, saying a withdrawal is contrary to the accelerated approval standards, the science on the biologic and the public health.